



# HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes

Zanele Ditse,<sup>a,b</sup> Maximilian Muenchhoff,<sup>c,d,e,f</sup> Emily Adland,<sup>c</sup> Pieter Jooste,<sup>g</sup> Philip Goulder,<sup>c,d,g</sup> Penny L. Moore,<sup>a,b,h</sup> Lynn Morris<sup>a,b,h</sup>

<sup>a</sup>Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa

<sup>b</sup>University of the Witwatersrand, Johannesburg, South Africa

<sup>c</sup>Department of Paediatrics and HIV Pathogenesis Programme, University of Oxford, Oxford, United Kingdom

<sup>d</sup>HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa

<sup>e</sup>Max von Pettenkofer Institute, Department of Virology, Ludwig Maximilian University Munich, Munich, Germany

<sup>f</sup>German Center for Infection Research (DZIF), partner site Munich, Germany

<sup>g</sup>Pediatric Department, Kimberley Hospital, Northern Cape, South Africa

<sup>h</sup>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa

**ABSTRACT** We have previously shown that HIV-1-infected children develop broader and more potent neutralizing antibody responses than adults. This study aimed to determine the antibody specificities in 16 HIV-1 subtype C-infected children who displayed exceptional neutralization breadth on a 22-multisubtype virus panel. All children were antiretroviral treatment (ART) naive with normal CD4 counts despite being infected for a median of 10.1 years with high viral loads. The specificity of broadly neutralizing antibodies (bNAbs) was determined using epitope-ablating mutants, chimeric constructs, and depletion or inhibition of activity with peptides and glycoproteins. We found that bNAbs in children largely targeted previously defined epitopes, including the V2-glycan, V3-glycan, CD4bs, and gp120-gp41 interface. Remarkably, 63% of children had antibodies targeting 2 or 3 and, in one case, 4 of these bNAb epitopes. Longitudinal analysis of plasma from a mother-child pair over 9 years showed that while they both had similar neutralization profiles, the antibody specificities differed. The mother developed antibodies targeting the V2-glycan and CD4bs, whereas bNAb specificities in the child could not be mapped until 6 years, when a minor V2-glycan response appeared. The child also developed high-titer membrane-proximal external region (MPER) binding antibodies not seen in the mother, although these were not a major bNAb specificity. Overall, exceptional neutralization breadth in this group of children may be the result of extended exposure to high antigenic load in the context of an intact immune system, which allowed for the activation of multiple B cell lineages and the generation of polyclonal responses targeting several bNAb epitopes.

**IMPORTANCE** An HIV vaccine is likely to require bNAbs, which have been shown to prevent HIV acquisition in nonhuman primates. Recent evidence suggests that HIV-infected children are inherently better at generating bNAbs than adults. Here, we show that exceptional neutralization breadth in a group of viremic HIV-1 subtype C-infected children was due to the presence of polyclonal bNAb responses. These bNAbs targeted multiple epitopes on the HIV envelope glycoprotein previously defined in adult infection, suggesting that the immature immune system recognizes

**Received** 18 May 2018 **Accepted** 14 June 2018

**Accepted manuscript posted online** 27 June 2018

**Citation** Ditse Z, Muenchhoff M, Adland E, Jooste P, Goulder P, Moore PL, Morris L. 2018. HIV-1 subtype C-infected children with exceptional neutralization breadth exhibit polyclonal responses targeting known epitopes. *J Virol* 92:e00878-18. <https://doi.org/10.1128/JVI.00878-18>.

**Editor** Guido Silvestri, Emory University

**Copyright** © 2018 Ditse et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Penny L. Moore, pennym@nicd.ac.za, or Lynn Morris, lynnmm@nicd.ac.za.

HIV antigens similarly. Since elicitation of a polyclonal bNAb response is the basis of next-generation HIV envelope vaccines, further studies of how bNAb lineages are stimulated in children is warranted. Furthermore, our findings suggest that children may respond particularly well to vaccines designed to elicit antibodies to multiple bNAb epitopes.

**KEYWORDS** epitope mapping, HIV envelope targets, HIV vaccines, HIV-1 subtype C, mother-child transmission, neutralization breadth, neutralizing antibodies, pediatric immunology, bNAbs

Fundamental differences exist between adult and pediatric HIV infection as a consequence of different transmission routes and immaturity of the pediatric immune system (1). The most significant difference is that HIV disease progression is more rapid in children and is associated with significantly higher levels of viral replication (2). Pediatric HIV infection is biphasic, with approximately 60% of deaths occurring before 3 years. Those children that survive beyond this usually show slow disease progression (3). About 10% of these children have normal CD4 counts in the context of high viral burden, which is only rarely seen in adult viremic nonprogressors (4). It was further shown that these pediatric nonprogressors (PNPs) had reduced CCR5 expression on long-lived memory CD4 T cells and low levels of immune activation (4). Protective HLA alleles play a less important role in nonprogressing HIV-1 infection in children, in contrast to adults (5). Furthermore, in adults, nonpathogenesis is associated with a high CD4 count and undetectable viral loads, whereas PNPs typically retain a persistently high viral burden (1, 4, 6). Previous studies have shown that neutralizing antibody responses in HIV-infected children arise early in the course of infection and are more potent and more broadly neutralizing than in adult infection (4, 7). These differences between adults and children provide a rationale for further characterizing humoral antibody responses during pediatric HIV-1 infection.

Broadly neutralizing anti-HIV antibodies (bNAbs) are considered an important component of an HIV vaccine and may also play a critical future role in treatment and cure strategies (8). Numerous studies have documented the presence of bNAbs in chronically infected adults (9–13). This has led to the isolation of a large number of broad and potent neutralizing monoclonal antibodies (MAbs) that have helped to define major sites of vulnerability on the HIV envelope, namely, the V2-glycan, V3-glycan, CD4 binding site (CD4bs), gp120-gp41 interface, and the membrane-proximal external region (MPER) (14). These targets provide a blueprint for immunogen design, although to date no envelope vaccines have been able to elicit bNAbs.

A previous longitudinal study of bNAbs in children has suggested that they arise earlier than in adults, and in some cases, bNAbs could be detected within the first year of life (7). Limited mapping data suggested that breadth was mediated either by multiple bNAb specificities that could not be deconvoluted or by bNAbs with novel specificities (7). Subsequently, a MAb was isolated and characterized from one infant (15). This bNAb, BF520.1, was shown to target the V3-glycan epitope on the HIV envelope and exhibited neutralization breadth of 58%. In addition, BF520.1 was shown to have low levels of somatic hypermutation compared with adult bNAbs targeting the same epitope, suggesting that the mechanisms governing development of bNAbs in children are different from those of adults.

We therefore sought to define bNAb specificities in a previously reported cohort of HIV-1 subtype C-infected children over 5 years of age who had high viral loads but normal CD4 counts and exceptionally high levels of bNAbs (4). Indeed, 70% (61/87) of children had plasma antibodies that neutralized  $\geq 50\%$  of viruses compared with only 19% of adults infected for a similar duration (4). In this study, we performed experimental mapping of bNAb specificities in 16 of these children. We showed that children develop bNAbs targeting epitopes similar to those of adults. However, we also demonstrated that the majority of children develop a polyclonal bNAb response targeting as many as four different epitopes. Lastly, we demonstrated that an infected mother-

**TABLE 1** Demographic and clinical features of 17 HIV-1-infected participants selected for epitope mapping

Participant ID	Age (yr)	Classification	Absolute CD4 (/mm <sup>3</sup> )	Viral load (copies/ml)	% Neutralization breadth <sup>a</sup>	GMT <sup>b</sup>
PID1_M <sup>c</sup>	35.5	Nonprogressor	509	22,000	100	1,204
PID1_C <sup>c</sup>	6.5	Nonprogressor	1,553	13,938	100	1,009
PID2	12.9	Nonprogressor	521	490,000	100	328
PID3	10.2	Nonprogressor	756	110,000	100	325
PID4	11.9	Nonprogressor	635	42,000	91	297
PID5	9.6	Nonprogressor	1,622	10,321	91	188
PID6	10.1	Nonprogressor	1,395	50,000	91	151
PID7	10.0	Progressor	327	22,467	91	386
PID8	11.6	Nonprogressor	1,115	6,430	86	197
PID9	8.6	Nonprogressor	1,120	58,400	86	181
PID10	10.7	Nonprogressor	1,330	11,900	82	194
PID11	10.1	Nonprogressor	717	140,000	82	166
PID12	10.5	Progressor	301	71,000	82	343
PID13	6.7	Progressor	334	387,134	82	268
PID14	9.6	Nonprogressor	1,877	4,574	73	450
PID15	11.1	Nonprogressor	1,310	1,585	73	296
PID16	11.5	Nonprogressor	1,032	99,000	60	196

<sup>a</sup>Neutralization breadth was measured against a multiclade panel of 22 viruses.

<sup>b</sup>GMT, geometric mean titer.

<sup>c</sup>Mother-child pair.

child pair developed equivalently high bNAb responses but that these target distinct neutralization epitopes, highlighting the role of multiple factors in bNAb development.

## RESULTS

### Clinical features of HIV-1 subtype C-infected children selected for this study.

We selected 16 HIV-1-infected children from two pediatric cohorts of nonprogressors and progressors plus one transmitting mother for epitope mapping based on their neutralization breadth and potency, as described in an earlier study (4). Clinical and demographic features of selected participants are shown in Table 1. The median age of the children was 10.1 years (interquartile range, 6.5 to 12.9), and all were antiretroviral treatment (ART) naive at the time of sample collection. The viral load ranged between 1,500 and 490,000 copies/ml, and the absolute CD4 count ranged between 300 and ~2,000 cells/mm<sup>3</sup>. This unusual phenotype of normal CD4 counts in a context of high viral burden was previously described for the larger cohort from which these children were selected (4). Neutralization breadth and potency of all 17 plasma samples were assessed against a multisubtype panel of 22 heterologous viruses (Fig. 1). Neutralization breadth ranged between 60 and 100%, and the geometric mean titers (GMT) ranged between 151 and 1,204 (Table 1). Three children plus the transmitting mother neutralized 100% of the subtype A, B, and C viruses. Although there was a significant correlation between neutralization breadth and viral load in the larger cohort (4), significance between these two variables was not maintained in this smaller selected group of broad neutralizers.

**Differential effect of gp120 adsorption on neutralization capacity of plasma suggests polyclonal bNAb responses.** To assess whether gp120-directed antibodies mediated neutralization breadth, plasma samples were adsorbed with ConC gp120 and tested against ConC, CAP45, and Q23.17 in a TZM-bl neutralization assay. Enzyme-linked immunosorbent assays (ELISAs) confirmed the depletion of ConC gp120-binding antibodies for all plasma samples (data not shown). Adsorption with ConC gp120 resulted in at least a 50% reduction in neutralization activity for 14/16 plasma samples when tested against ConC, 8/16 samples for CAP45, and 5/16 samples for Q23.17 (Fig. 2). For one child (PID1\_C), adsorption did not result in significant depletion of neutralization activity (>50%) against any of the 3 viruses, suggesting that neutralization breadth in this child is mediated by trimer-specific or gp41-directed antibodies. Interestingly, the effect of adsorption of gp120-specific antibodies on neutralization varied per virus for most plasma samples. For example, in PID12, gp120-directed antibodies neutralized ConC, partially neutralized Q23.17, but failed to neutralize CAP45, whereas

PTID	SUBTYPE C																SUBTYPE B										SUBTYPE A										Negative control	
	ComC	Du151.2	Du156.2	Du172.17	CAP45.G3	ZM197M	CAP239.G3	CAP256.SU	ZM24M	PVD.4	6535.3	TR0.11	MITO.416	AC10.0.29	QH0692.4	Q23259.p2.17	Q23.17	Q168.a2	BG505	Q842.p12	Q769.p22	Q461.e2	MuLV	MuLV														
PID1	15,023	1,926	3,678	3,48	11,923	181	273	1,738	939	137	1,061	273	914	614	243	18,704	10,207	1,061	1,845	4,429	763	141	40	40														
PID1 C*	3,658	2,867	8,492	271	6,840	1,027	18,669	893	763	204	350	2,885	80	119	452	2,806	1,951	238	736	2,886	2,300	342	40	40														
PID2	1,573	219	293	416	6,911	345	1,598	638	74	19	119	2,011	2,851	485	52	1,531	1,623	254	193	141	118	52	40	40														
PID3	681	538	235	215	593	495	1,052	216	102	659	690	277	152	36	373	940	231	319	106	106	110	31	40	40														
PID4	1,784	1,442	664	174	6,962	485	2,517	602	103	1,571	198	40	333	206	733	104	111	175	322	338	40	40	40	40														
PID5	2,870	1,211	74	73	644	104	623	192	46	233	115	597	294	40	319	724	55	394	143	123	40	40	40	40														
PID6	688	432	591	269	320	102	330	237	102	78	122	126	225	41	224	84	88	192	90	31	40	40	40	40														
PID7	2,900	521	989	709	4,171	37	140	409	424	40	184	54	879	544	191	144	141	576	741	631	40	40	40	40														
PID8	695	285	600	660	404	81	126	238	343	160	42	40	40	133	363	66	40	294	40	171	40	40	40	40														
PID9	3,161	715	446	222	668	843	154	263	40	133	412	299	199	88	993	176	164	197	295	40	79	40	40	40														
PID10	795	2,435	4,509	202	2,629	337	289	68	242	49	109	52	192	58	88	48	288	40	130	44	40	40	40	40														
PID11	355	327	341	110	32,163	91	41	96	57	40	582	110	64,160	623	40	107	27,391	198	4,231	219	40	40	40	40														
PID13	7,983	7,983	788	637	562	50	280	727	164	83	1,871	412	40	759	113	44	911	40	204	83	40	40	40	40														
PID14	2,668	2,426	512	789	3,415	203	600	566	281	40	3,508	283	17,319	281	525	40	17,911	40	684	40	40	40	40	40														
PID15	2,014	176	215	78	4,154	125	662	1,842	40	40	623	40	720	72	40	10,598	696	368	5,763	40	40	40	40	40														
PID16	2,521	725	1,685	400	7,717	1,367	274	1,363	40	266	40	266	40	157	627	43	40	40	40	40	40	40	40	40	40													



**FIG 1** Breadth of plasma neutralizing activity from 16 children and 1 transmitting mother. Plasma samples were tested against 22 heterologous viruses from subtypes A, B, and C using the TZM-bl neutralization assay. Neutralization titers for each virus-plasma combination are shown as the reciprocal of the plasma dilution required to inhibit 50% virus infection (ID<sub>50</sub>). Data are shown as a heat map, with titers of >1,000 in red, those between 100 and 999 in orange, and those of <100 in light yellow, as indicated by the key. Titers of 1:40 indicate no neutralization. MuLV was included as a negative control. These data were used to derive the GMT included in Table 1.

	% gp120 directed responses		
	ConC	CAP45	Q23.17
PID1 C	44	19	39
PID2	55	36	<10
PID3	77	<10	60
PID4	78	64	32
PID5	87	68	31
PID6	70	77	47
PID7	65	37	24
PID8	59	63	<10
PID9	<10	70	12
PID10	95	82	87
PID11	71	43	18
PID12	84	<10	54
PID13	93	15	87
PID14	90	49	80
PID15	56	59	40
PID16	89	89	25

KEY
<10
10-49
>50

**FIG 2** Differential effect of gp120 adsorption on neutralization suggests polyclonality. Anti-gp120 antibodies were depleted from plasma samples of all 16 children using tosyl-activated beads coated with ConC gp120 protein. Adsorbed plasma were tested for neutralization activity against ConC and heterologous viruses CAP45 and Q23.17. The percentage of gp120-directed neutralization was calculated as the reduction in ID<sub>50</sub> of plasma incubated with gp120-coated beads relative to that of blank beads  $(((\text{blank beads} - \text{gp120-coated beads})/\text{blank beads}) \times 100)$ . Plasma samples where >50% of neutralizing activity was depleted by gp120 are colored red, and those with no depletion are colored blue. Those with some gp120-directed antibodies are colored yellow.

in PID10 virtually all the neutralization activity against ConC, CAP45, and Q23.17 was gp120 directed (Fig. 2). This variable effect of gp120 adsorption by virus suggested that in most cases, breadth was mediated by polyclonal responses, some of which were gp120 specific.

**The majority of children develop antibodies targeting the V2-glycan and V3-glycan epitopes.** Pseudoviruses containing mutations at key residues in the V2-glycan and V3-glycan epitopes were used to screen for these specificities in plasma samples. For V2-glycan antibodies, we used both N160A/K and K169E mutants, as some V2-directed antibodies, such as the CAP256-VRC26 lineage, exhibit limited glycan dependence (16, 17). Specificity was assigned when neutralizing activity for the mutant virus was  $\geq 3$ -fold less than that of the wild-type virus in 2 or more backbones. By these criteria, 9 of the 16 children (56%) developed antibodies directed at the V2-glycan epitope (Fig. 3), although the effect varied by virus backbone. For example, in PID15, either a 160A or 169E mutation completely abrogated neutralization in CAP45, suggesting that the V2 specificity accounts for all activity against this virus. However, neither BG505 nor CAP256\_SU was neutralized by V2-directed antibodies, suggesting that other specificities in this child were responsible for neutralizing these viruses. Similarly, a >10-fold effect was observed for PIDs 2, 5, 13, and 14 in CAP45, but the effect was less pronounced for other backbones. Several plasma samples were more affected by the K169E mutation than by the N160A mutation in CAP45, suggesting less dependence on the glycan moiety in this epitope, similar to CAP256 MAbs (16, 17). Consistent with published data, neutralization by positive-control MAbs CAP256.08 and PG9 was reduced/knocked out in V2-glycan mutants (16–18).

To assess V3-glycan antibodies, we deleted the N332 glycan in three backbones, TRO.11, ConC, and Du156.12. Using the same cutoffs, a V3-glycan specificity was assigned to a third (5/16, 31%) of the children, of whom four (PIDs 2, 5, 7, and 13) also showed evidence of V2-glycan-directed bNAbs (Fig. 3). Consistent with previous data (19), we observed a knockout in neutralization activity for PGT128 against the N332A mutant in all viruses tested. Overall, our data suggest that bNAbs directed at the

PTID	V2-glycan responses						V3-glycan responses			Specificity
	CAP45 N160A	ConC N160A	Du156 N160K	CAP45 K169E	BG505 N332+ K169E	CAP256 SU K169E	TRO.11 N332A	ConC N332A	Du156 N332A	
PID1 C	3.5	2.2	2.0	2.8	1.1	1.0	0.6	2.3	1.0	
PID2	1.4	0.9	1.7	39.0	0.7	4.1	2.8	9.9	2.0	V2
PID3	1.3	3.0	1.0	1.6	0.9	1.0	1.5	5.1	3.0	V3
PID4	0.6	2.0	0.7	3.5	0.3	1.0	1.5	5.3	1.0	
PID5	5.0	3.5	3.0	17.0	1.0	4.6	3.0	3.0	0.5	V2 and V3
PID6	8.6	3.2	1.1	5.1	1.0	2.3	0.9	3.1	1.0	V2
PID7	1.8	5.4	3.1	1.3	1.2	4.3	1.0	6.3	2.0	V2
PID8	1.8	3.7	1.0	1.1	0.7	1.8	1.6	4.5	3.0	V3
PID9	0.2	0.2	0.5	0.4	1.5	1.1	2.1	1.9	2.0	
PID10	1.4	1.6	1.6	1.7	5.0	10.8	3.0	1.9	2.0	V2
PID11	3.2	2.4	0.5	8.7	1.3	0.8	3.0	1.9	2.0	V2
PID12	0.8	3.3	0.2	1.4	1.4	0.5	0.3	1.8	0.4	
PID13	6.1	6.0	0.2	36.9	0.8	0.5	1.6	2.2	2.0	V2
PID14	6.9	1.0	0.6	29.5	1.0	0.5	3.0	3.3	1.0	V2 and V3
PID15	>100	4.7	3.0	>100	1.0	0.8	3.0	0.7	0.2	V2
PID16	1.4	2.0	0.6	1.8	0.3	0.8	3.0	5.8	1.0	V3
CAP256.08	>100	>100	10.0	>100	>100	>100	1.0	1.0	0.5	V2
PG9	>100	>100	>100	>100	>100	>100	1.0	1.0	0.5	V2
PGT128	1.0	1.0	1.0	1.0	1.0	1.3	>100	>100	>100	V3

KEY
3-5 FOLD
5-10 FOLD
10-100 FOLD
>100 FOLD

**FIG 3** Majority of children develop neutralizing antibodies directed at V2-glycan and V3-glycan epitopes. Plasma samples from 16 children were assessed for V2-glycan antibodies using N160A/K and K169E mutants and for V3-glycan-directed responses using N332A mutants. Three heterologous viruses were assessed for each mutation and results are color coded with 3- to 5-fold reduction in neutralization activity shown in yellow, 5- to 10-fold reduction in orange, 10- to 100-fold reduction in red, and >100-fold reduction in dark red. V2/V3 specificity was assigned when plasma showed  $\geq 3$ -fold reduction in at least 2 backbones. The V2 MAbs CAP256.08 and PG9 and the V3 MAb PGT128 were used as positive controls and showed the expected activity.


V2-glycan epitope are the most common in HIV-1 subtype C-infected children with broad neutralizing responses.

**CD4bs-directed plasma antibodies are frequently detected in children.** We used the wild-type RSC3 protein and its RSC3 $\Delta$ 371I/P363N mutant to assess CD4bs binding and neutralization activity. Binding of six plasma samples (PIDs 4, 5, 6, 8, 10, and 11) to the RSC3 $\Delta$ 371I/P363N CD4bs mutant was significantly lower than that to the wild-type RSC3 protein, suggesting the presence of CD4bs-directed antibodies in these participants (Fig. 4). This pattern was comparable to that of the positive-control MAb, VRC01 (Fig. 4), which was isolated using this RSC3 probe. Overall, the binding assays demonstrated that a third of children (6/16, 38%) had CD4bs-directed activity. Protein competition assays using the RSC3 protein verified CD4bs-directed neutralization activity in all six children (Fig. 4B). This was confirmed by at least 30% reduction in neutralization activity following incubation with RSC3 protein. This effect was, however, only observed in one virus for 5 of the 6 children (Fig. 4B). Incubation with the RSC3 $\Delta$ 371I/P363N CD4bs mutant did not impact neutralization activity against any of the 4 viruses tested (data not shown).

In addition to binding assays, neutralization assays were performed using viruses with mutations in the CD4bs epitope (N276A, N279A, and R456W). The N276 and N279 residues are important contact sites for HJ16-like CD4bs antibodies, while the R456 residue is critical for epitope recognition for VRC01, 3BNC117, N6, and VRC27 (20). No reduction in neutralization activity was observed with the N276A and N279A mutants for any participants (data not shown). However, a 4-fold reduction in neutralization activity using the R456W mutant was observed in two participants (PID4 and PID10) (data not shown), verifying the data using the RSC3 proteins. Overall, binding and neutralization assays suggest that  $\sim 40\%$  of children develop CD4bs-directed antibody responses that contribute to broad neutralization activity.

**Anti-MPER antibodies rarely confer broad neutralizing activity in children.** The presence of MPER-directed antibodies in plasma samples was measured using the HIV-2/HIV-1 MPER chimeras as previously described (21). Four of 16 children showed 50% reciprocal plasma dilution ( $ID_{50}$ ) titers of >750 against either C1 (contains the subtype B HIV-1 MPER sequence) or C1C (subtype C HIV-1 MPER sequence). Fine






**FIG 4** Mapping of CD4bs antibodies by binding and neutralization using the RSC3 protein. (A) Plasma samples were tested for binding to the RSC3 protein (solid line) and the CD4bs mutant protein RSC3 $\Delta$ 371I/P363N (dotted line) by ELISA. Shown are curves of 6 children with binding to the RSC3 protein but not the mutant protein, similar to VRC01 and suggestive of CD4bs antibodies. PID14 showed equivalent binding to both proteins and was used as a negative control. (B) The RSC3 protein was also used in a competition neutralization assay to detect CD4bs antibodies in the same 6 participants. Neutralization of Du156.12, CAP45, ConC, and Q23.17 was measured following incubation with RSC3. A reduction in neutralization of  $\geq$ 30% (dotted line) was considered positive. Five of the 6 children showed activity against one virus, most commonly CAP45. VRC01 was used as a positive control, with RSC3 blocking neutralization of all 4 viruses as expected.

**A**

Chimera	MPER Sequence	2F5	4E10	Z13.e1	PID1_C	PID3	PID7	PID10
HIV-2 7312A	NMYELQKLNSWDVFGNWFDLASWVKYIQYGVYIV	10	10	10	40	40	40	40
C1	NMYELLALDKWASLWNWFDITKWLWYIKYGVYIV	0.04	0.03	0.34	1,190	7,079	753	1,431
C1C	NMYELLALDSWKNLWNWFDITKWLWYIKYGVYIV	10	0.05	0.51	384	5,988	337	1,227
C4GW	NMYELQKLNSWDVFNWFDITKWLWYIKYGVYIV	10	0.04	0.25	338	6,118	410	1,521
C8	NMYELQKLNSWDSLWNWFDITKWLWYIKYGVYIV	10	0.04	0.85	61	5,140	88	800
C4	NMYELQKLNSWDVFGNWFDITKWLWYIKYGVYIV	10	0.04	5.69	40	4,923	40	712
C6	NMYELQKLNSWDVFGNWFDITSWIKYIQYGVYIV	10	0.07	6.10	40	701	40	40
C3	NMYELLALDKWASLWNWFDLASWVKYIQYGVYIV	0.06	10	10	40	40	40	40
C7	NMYELQALDKWAVFGNWFDLASWVKYIQYGVYIV	0.01	10	10	40	40	40	40

IC <sub>50</sub>	ID <sub>50</sub>
1-10	<100
0.1-0.9	100-999
0.01-0.09	>1,000

**B**



**FIG 5** Mapping of anti-MPER neutralizing activity in four children. (A) Plasma samples from 4 children with high levels of neutralizing activity against the HIV-2/HIV-1 MPER C1 and C1C constructs were tested against 6 additional chimeric constructs containing point mutations to map known MPER antibodies. Also shown are the sequences carried by the MPER of each engrafted HIV-2/HIV-1 chimeric construct. Mutated amino acids are indicated in blue. Titers are shown as ID<sub>50</sub> and are color coded with HIV-2 used as a negative control. 2F5, 4E10, and Z13e1 were used as positive controls. (B) Plasma from PID3 was incubated either with magnetic beads coated with MPR.03 peptide (left) or incubated directly with the MPR.03 peptide (right) to adsorb anti-MPER antibodies. MPER broad neutralization activity against untreated (solid lines) and adsorbed (dotted lines) samples was tested against heterologous viruses C1C and COT6. Adsorption of anti-MPER antibodies in PID3 reduced neutralization of heterologous viruses.

mapping of these 4 samples was performed using additional chimeras, C4, C4GW, C6, and C8, that contain point mutations in the MPER (21). PID3 and, to some extent, PID10 had a 4E10-like footprint characterized by potent neutralization of C4GW, C4, C8, and C6 (Fig. 5A). Two samples, PID1\_C and PID7, had similar patterns, neutralizing C4GW and C8 but not C4 and C6, a footprint similar to that of Z13e.1 (Fig. 5A). None of the four plasma samples showed neutralization of C3 and C7 (which contain the 2F5 epitope), suggesting that recognition of this N-terminal MPER region is uncommon. These data indicate that the anti-MPER antibodies in children recognized an epitope within the C terminus of the MPER, similar to bNAb 4E10.

To assess the contribution of the MPER-directed antibodies to broad neutralization activity, adsorption and competition neutralization assays were performed using the MPR.03 peptide. PID3, who had the highest titers against the HIV-2/HIV-1 MPER chimeras, showed a significant reduction in neutralization activity in both assays. This effect was seen against C1C and COT6 (Fig. 5B) but not in another 3 heterologous viruses (data not shown). In contrast, no reduction in neutralization activity was observed for PID1\_C, PID7, and PID10 against any of the viruses tested (data not shown). Overall, MPER antibodies were therefore shown to contribute to breadth in only 1/16 children in this cohort.

**Antibodies directed to the gp120-gp41 interface detected in more than half of the children.** To determine whether children have antibodies directed at the gp120-



gp41 interface, including the fusion peptide (FP), plasma samples were screened using peptide competition assays, ELISAs, and neutralization assays with epitope-ablating mutants. The FP9 peptide inhibited >30% neutralization against at least 2 of the 3 viruses (Du156.12, ConC, and BG505) in 7 children, suggesting the presence of fusion peptide-directed antibodies (Fig. 6A). As described by Kong et al., we also observed >80% reduction in neutralization activity against all 3 viruses for VRC34, a fusion peptide-specific antibody used as a positive control (22) (Fig. 6A). ELISA data demonstrated binding responses to the FP9 peptide for 11 children (Fig. 6B), six of whom also exhibited evidence of FP-mediated competition (Fig. 6B, red curves). The remaining five ELISA-positive children did not show inhibition of neutralization (Fig. 6B, shown in blue). Interestingly, no binding antibodies to FP9 were observed for PID1\_C, although FP9-specific neutralizing responses were detected by competition (Fig. 6A and B).


To further assess FP-directed responses in children, we also used a viral mutant containing a threonine insertion after residue 514 in the FP of isolate BG505. This mutation confers complete resistance to VRC34 (22). A 10- and 8-fold decrease in neutralization activity against this mutant strain was observed for PID14 and PID15 (Fig. 6C), both of whom also had FP responses by ELISA and competition neutralization assays (Fig. 6A and B), suggesting that the fusion peptide is a target for bNAbs in these two children.

Since gp120-gp41 interface bNAbs 8ANC195, PGT151, 35O22, VRC34, and CAP248-2B target distinct but overlapping epitopes (23), we tested mutants critical for each bNAb. Three children had antibodies sensitive to deletion of the glycan at position 88 in gp120, with fold effects from 10 to >100, one of whom, PID12, was also shown to have FP bNAbs. The N88 glycan is critical for epitope recognition for PGT151, 35O22, and VRC34 (23) (Fig. 6C). We also observed sensitivity to the N88A and N234A mutations for PID5 and for PID6 against the N234A mutation only, as has been reported for 8ANC195-like antibodies (14) (Fig. 6C). Three plasma samples, including PID5, showed a minor effect with N611D, and PID6 neutralization was reduced by N637A; both mutations affect PGT151, 35O22, and VRC34 neutralization.


We next screened plasma samples using the CAP45 CS-Mut virus that contains 6 mutations in the gp120-gp41 cleavage site, which we described previously (23). These mutations mediate escape from PGT151 and CAP248-2B-like antibodies but result in exposure of the MPER detected through increased neutralization sensitivity (23). As previously reported, CAP45 CS-Mut was >100-fold more resistant to PGT151 but showed enhancement of 35O22 and 4E10 (Fig. 6C). A 4-fold reduction in neutralization activity was observed against CAP45 CS-Mut in one child, PID13, suggesting that PGT151/CAP248-like antibodies contribute to neutralization activity in this participant (Fig. 6C). We saw enhanced neutralization activity in 3 participants (PID3, PID8, and PID15), suggesting these children had MPER-directed or 35O22-like antibodies (Fig. 6C). In support of this, we observed MPER activity in PID3 (Fig. 4A and B) and, to some extent, PID8 (C1C titer of 188; data not shown). Overall, our data demonstrate that more than half of children (9/16, 56%) develop antibodies targeting regions within the gp120-gp41 interface.

**Neutralization breadth in children is mediated by multiple antibody specificities.** Combining all the mapping data generated in this study, we noted that the majority of children (10/16, 63%) developed more than one antibody specificity (Fig. 7A). Most had 2 specificities, although 3 children had three specificities and one child, PID5, developed antibodies targeting four different epitopes (Fig. 7B). None of the children developed bNAbs that targeted the MPER epitope only. No association was observed between neutralization breadth and the number of bNAb specificities detected in each child's plasma sample.

**Mother-child pair develops antibodies targeting distinct bNAb epitopes.** To further understand factors associated with development of neutralization breadth, we studied a mother-child pair over a 9-year period. The mother (PID1\_M) was enrolled into the study approximately 8 years after infection and had a viral load of 139,000 that



**FIG 6** Children develop antibody responses to the gp120-gp41 interface, including the fusion peptide. (A) A reduction in neutralization of Du156.12, ConC, and BG505 was measured following incubation with the fusion peptide FP9. A cutoff of  $\geq 30\%$  (dotted line) was considered significant. Of the 16 children, 7 showed activity against 2 or 3 viruses that was FP directed. VRC34 was used as a positive control. (B) Plasma samples from 16 children were assessed for binding to FP9 using ELISA. Samples where FP9 competed for neutralization in panel A are shown in red, blue represents ELISA-positive samples where FP9 did not compete for neutralization, and black represents samples that were negative for both binding and neutralization. VRC34 was used as a positive control. (C) Mapping of responses using mutant viruses to the fusion peptide (THR514B), gp120-gp41 (residues 88, 234, 611, and 637), and the cleavage site (CAP45 CS Mut that contains 6 mutations known to expose the MPER). The fold change in neutralization breadth for the mutants relative to the wild-type strains is shown as a heat map for all 16 plasma samples. Loss of activity is shown in yellow (3- to 5-fold), orange (5- to 10-fold), and red (>10-fold), and enhancement is shown in blue. PGT151, 35O22, 4E10, VRC34, and CAP248-2B were used as positive controls. The overall specificity is shown in the last column, with those in brackets derived from data shown in panels A and B.




**FIG 7** The majority of children develop antibodies targeting multiple epitopes. (A) Pie chart showing a summary of mapped neutralization epitopes targeted by plasma antibodies from children. (B) Breakdown of specificities detected in children with more than one bNAb. Shown in the last column is the total number of mapped specificities.

fluctuated over time but remained high (Fig. 8A). Her CD4 count remained above 500 cells/ml. The child’s (PID1\_C) viral load was greater than 2 million copies/ml at birth and declined slowly over time but was above 100,000 copies/ml at 9 years. At enrollment into this study the mother’s plasma neutralized 60% of viruses in the 22-virus panel tested, rising to 100% over the next 9 years (Fig. 8B). In contrast, no neutralizing activity was observed in the child at 3 months, but breadth emerged over time and by 6 years of age onwards the child’s plasma also neutralized 100% of the viruses tested (Fig. 8B). Geometric mean titers were >1,000 for both mother and child after more than 9 years of infection.

We had initially mapped the 6- and 9-year postenrollment time point for the child and mother, respectively. To examine the evolution of bNAb responses in the mother-child pair we mapped the longitudinal samples (Fig. 8C). Comparison of CAP45 and CAP45 K169E titers showed the development of a V2-glycan response from 3 years onwards in the mother. This effect was verified in 2 different backbones (CAP45 and BG505 [data not shown]). A slight V2 dependence was observed for the child at 6 and 7 years, suggesting that V2-glycan bNAbs were not a major specificity in the child. We observed no V3 responses in either mother or child, as there were no differences between the N332A mutant relative to the wild-type strain. CD4bs activity was seen in the mother at later time points; however, this specificity was not evident in the child. The child developed MPER binding antibodies from 2 years of age, which persisted until 6 years of age and then declined over time. No MPER activity was observed in the mother. Overall, our data suggest that the mother-child pair developed different antibody profiles, with antibodies directed at the V2-glycan and CD4bs epitopes evolving in the mother while the major specificities mediating breadth in the child could not be mapped.

**DISCUSSION**

Although many studies have examined the development and targets of bNAbs in adults (14, 24–28), a limited number of studies have assessed these responses in children following HIV-1 infection (4, 7, 15). We and others have shown that children mount broader and more potent antibody responses than adults, which indicates fundamental differences in the way children respond to HIV antigens (4, 7). In the present study, we used several approaches to reveal the targets of bNAbs among a large number of preselected HIV-1 subtype C-infected children. We observed that although neutralizing antibody specificities were similar to those of adults, the majority of children had bNAbs targeting multiple epitopes. This polyclonality may be due to the long duration of infection and high viral loads in this group of children, features strongly linked to the development of neutralization breadth in adults (10, 11, 24, 25, 29). These data support the notion that children mount stronger and more complex responses to HIV antigens than adults, which may have implications for the immunogenicity of HIV vaccines in children.



**FIG 8** Mother-child pair develop antibodies that target distinct epitopes. (A) Longitudinal viral load (circles) and CD4 counts (triangles) for mother-child pair. Mother's data (PID1\_M) are shown in red, and (Continued on next page)

Polyclonal bNAb responses in adults have been previously reported (10, 19, 30–32); however, this occurs at a much lower frequency than that observed here in children, where 63% had between 2 and 4 specificities. Our previous data from the CAPRISA cohort suggested that of the 7 adult women who developed bNAbs, only 1 had more than one specificity (33). Similarly, longitudinal studies from the protocol C adult cohort demonstrated multiple bNAb specificities in only 3/42 (7%) participants (10). However, this may be an underrepresentation, since many adult mapping studies are performed earlier in infection than with the children in this study.

Examples of adults with multiple specificities following long-term infection have been reported, such as the single donor from whom the antibodies 35O22 and 10E8 were isolated after 20 years of infection (34, 35). Furthermore, the transmitting mother in this study was shown to have at least 2 bNAb responses. In this case, she was a highly unusual viremic nonprogressor who maintained normal CD4 counts for over 17 years and a median viral load of 85,000 copies/ml (Fig. 8). Collectively, these data suggest that long duration of persistent exposure to high antigenic load, which is more common in children, can facilitate high levels of bNAb activity targeting multiple neutralization epitopes.

Previous reports have shown that bNAbs arise more rapidly in children and can be detected within a year of infection (7). This was also seen in the longitudinal sampling of PID1\_C, where some neutralizing activity was detected by 1 year. Over the next 6 years this increased to 100% neutralization of the panel, remaining at these levels for another 3 years. In adults, neutralization breadth generally takes up to 3 years to emerge, although cases of earlier detection of neutralizing activity have been reported (18, 25, 36). Further studies are needed to determine whether children have unique immunologic features that shorten the normally long process associated with the development of bNAbs. The isolation of MAb BF520.1 from an infant targeting the V3-glycan epitope on the HIV envelope, which exhibited low levels of somatic hypermutation and few indels, supports this possibility (15). Breadth in children may also be the result of their ability to generate new B cell lineages for a longer period of time, whereas data in adults suggests new bNAb specificities rarely emerge after 4 to 5 years of infection (25, 29).

The majority of children had responses directed at the V2-glycan epitope. This is similar to findings in adults (10, 19, 25, 32), suggesting that this antigenic site on the HIV-1 envelope is dominant in adult and pediatric HIV infection. The high proportion of CD4bs responses in this cohort may also be a consequence of the long duration of infection, as this is a prerequisite for this class of antibodies, which requires the accumulation of high levels of somatic hypermutation over many years (20, 37). However, isolation and genetic characterization of CD4bs MAbs from children is needed to address this question. Binding responses to the fusion peptide were observed in the majority of children, similar to a subtype B adult cohort, where 42% of the participants had this specificity (22). In contrast, MPER responses were rarely found in children, which is similar to the case for adults (13, 31, 38, 39). Structural constraints in accessing

#### FIG 8 Legend (Continued)

the child's data (PID1\_C) are shown in blue. Stars indicate the time points used for plasma mapping. Absolute CD4 counts with the median and 10th and 90th percentiles for normal uninfected children over the first 10 years of life are shown in gray (53, 54). (B, top) Kinetics of development of neutralization breadth in the mother-child pair over a 9-year period. Shown is the percentage of viruses neutralized in a 22-virus panel with mother shown in red and child in blue. (Bottom) Longitudinal geometric mean  $ID_{50}$  titers (GMT) of all viruses in the 22-virus panel for mother and child. (C) Mapping of the specificities over time in mother and child. Longitudinal samples were assessed for V2-glycan using the K169E mutant in CAP45 relative to the wild-type strain. V3-glycan-directed responses were assessed using the N332A mutant in ConC relative to the wild-type strain. CD4bs activity was assessed by the RSC3 and the RSC3Δ3711/P363N CD4bs mutant in ELISA. MPER responses were determined using the MPER chimeric constructs C1 (black) and C1C (gray). Wild-type strains are shown in solid lines and closed circles, and mutants are shown in dotted lines. Mother's data (PID1\_M) are shown on the left, and the child's data (PID1\_C) are on the right. Mother's samples were missing at time points 3, 6, and 7 years of the child's age.

the MPER on gp41 as well as the autoreactivity of MPER-targeting antibodies are thought to be some of the factors that contribute to the restricted induction of responses against this site (40, 41). PID3 had the highest titers of MPER bNAbs and showed enhanced neutralization of the CS mutant, which has an exposed MPER region (23). In addition, high titers of antibodies against the fusion peptide in PID3 further supports the conclusion that gp41 was exposed on the virus that infected this child.

The presence of multiple antibody specificities did not correlate with neutralization breadth, as exemplified by PID5, who developed 4 distinct bNAb specificities but did not neutralize all viruses in the panel. Despite the array of techniques used here, neutralization breadth in some children could not be completely mapped, suggesting the possibility that bNAbs with novel specificities were also present, as has been reported in adult cohorts. In particular, breadth in PID1\_C could not be clearly mapped, and the lack of adsorption with gp120 suggested that the bNAbs were trimer specific or targeted gp41. Isolation of MAbs from this child would therefore be of interest.

Mother-to-child transmission provides a unique setting to examine the role of viral and host factors that shape bNAb responses. This study demonstrated that the mother-child pair developed bNAbs targeting distinct neutralization epitopes. The high degree of viral and host genetic relatedness suggests that multiple factors shape the development of bNAbs. There was no neutralizing activity in the child at 3 months of age, indicating that responses in the child arose *de novo* and that maternal bNAbs, if present, had waned to below detectable levels. The bottleneck in HIV mother-to-child transmission is well described, with children often becoming infected with a minor variant (42, 43). Antibody specificities in both mother and child evolved continuously, and studies are ongoing to examine viral evolution and escape pathways in this pair.

Most studies aimed at HIV vaccine development have been conducted in adults. However, studies in infants have demonstrated that HIV vaccination induces strong immune responses (44, 45). Importantly, Fouda et al. reported robust and durable anti-V1V2 IgG antibody responses to MF59-adjuvanted HIV vaccines in HIV-exposed infants compared with those of RV144 recipient adults (46). These differences in vaccine responses between adults and infants were shown to be attributable to modulation of gp120-directed responses by adjuvants (47). Our finding that children develop broader and more potent responses to HIV infection suggests that they respond better to vaccines than adults.

In summary, our study demonstrates that children who develop broad and potent antibodies target multiple specificities directed at previously identified epitopes. This suggests that children are fundamentally better at generating bNAb responses than adults (1, 4, 6, 7, 46, 47). It will be important to understand how these responses are induced during infection and whether this is due to the unique immunological environment of the immature immune system that allows multiple B cell lineages to thrive. Isolation and characterization of MAbs from children will also help to address this. Importantly, our data suggest that children respond well to vaccine immunogens currently under clinical evaluation. Testing of bNAb-based HIV vaccines in children should therefore be a priority.

## MATERIALS AND METHODS

**Study population.** This study included ART-naive, HIV-1 subtype C-infected PNPs and progressors recruited from Kimberley and Durban, South Africa, as part of a study to determine the immunological factors associated with nonpathogenesis in children (4). The PNP cohort consists of ART-naive children with CD4 counts of  $>750$  cells/mm<sup>3</sup> and viral loads of  $>14,000$  copies/ml who have not met the clinical criteria for ART initiation. The progressor cohort consists of ART-naive children whose absolute CD4 count had declined to  $<500$  cells/mm<sup>3</sup> and had viral loads of  $>70,000$ ; these children are at the current threshold of ART initiation (4) according to national guidelines for ART initiation at the time when the participants were recruited. For this study, plasma samples collected in EDTA from 16 children with the highest neutralization breadth were selected for epitope mapping. For child PID1\_C (also known as 517-C), samples from the transmitting mother were also tested. Ethical approval was obtained from the University of the Free State Ethics Committee, University of KwaZulu-Natal Biomedical Research Ethics Committee, and University of Oxford Research Ethics Committee (4).

**Adsorption of anti-gp120 antibodies.** Anti-gp120 antibodies were depleted using monomeric wild-type ConC gp120 covalently coupled to tosyl-activated magnetic beads as described previously (31,



48, 49). Adsorbed plasma samples were assessed in ELISAs to confirm depletion of anti-gp120 antibodies and in the TZM-bl neutralization assay against HIV-1 to assess residual activity (31, 48, 49).

**Neutralization assays.** Neutralization was measured as the reduction in luciferase gene expression following a single round of infection of TZM-bl cells with Env-pseudotyped viruses (50). Titers were calculated as the 50% inhibitory concentration ( $IC_{50}$ ) or the reciprocal plasma dilution ( $ID_{50}$ ) causing a 50% reduction of relative light units (RLU) compared to results for the virus-treated or untreated control wells (50). Mutations were made in the following backbones: TRO.11, ConC, Du156.12, CAP45.G3, Du151.2, BG505 N332+, and CAP256 SU. BG505 N332+ is a BG505 strain where a glycan at position 332 was knocked in, and CAP256 SU is the superinfecting virus from CAPRISA participant CAP256. For neutralization competition assays, peptides or proteins were added to each well at a concentration of 250  $\mu$ g/ml. This included the synthetic biotinylated fusion peptide, FP9-biotin, with the sequence AVGGAVFL (22), the MPR.03 peptide with the sequence KKKNEQELLELDKWASLWNWFDITNWLWYIRKKK (51), and the resurfaced stabilized gp120 core (RSC3) and its CD4bs mutant, RSC3 $\Delta$ 3711/P363N (52). Proteins/peptides were incubated with serially diluted MAbs or human plasma for 30 min at 37°C before addition of pseudovirus. The mixture was further incubated for 30 min at 37°C. TZM-bl cells were added at 0.5 million cells/ml and incubated for 48 h, followed by cell lysis and measurement of luciferase activity.

**Detection of antibodies targeting the MPER.** Anti-MPER activity was measured using chimeric HIV-2/HIV-1 MPER constructs (51). Plasma responses of an  $ID_{50}$  of >750 against either C1 or C1C were considered positive, and these were further investigated using adsorption experiments. Adsorption experiments were performed using streptavidin-coated magnetic beads (DynaL MyOne Streptavidin C1; Invitrogen) incubated with biotinylated peptides carrying the MPR.03 sequence as described previously (51). Adsorbed plasma samples were tested by ELISA to confirm depletion of anti-MPER antibodies and in TZM-bl neutralization assays to assess the contribution of MPER antibodies to breadth (51).

**ELISA.** MPER, RSC3, and fusion peptide ELISAs were performed as described previously (21, 22, 52). Briefly, 96-well ELISA plates (Corning, USA) were coated with 2  $\mu$ g/ml of protein/peptide overnight. Coated plates were washed with phosphate-buffered saline (PBS) containing 0.05% Tween (dilution buffer) and blocked with 5% goat serum, 5% skim milk in dilution buffer for 1 h at 37°C. A 100-fold dilution of each plasma sample was added to the wells, titrated, and incubated for 1 h at 37°C. Unbound antibodies were removed by 4 washes before addition of goat anti-human IgG peroxidase-conjugated (KPL) at a 1:1,000 dilution. Following incubation with the secondary antibody, the wells were washed four times and developed using 1-Step Ultra TMB substrate (Thermo Scientific, Waltham, MA, USA). The reaction was stopped with 0.2 M  $H_2SO_4$ , and adsorbance was read at an optical density of 450 nm on a microplate reader (Molecular Devices).

## ACKNOWLEDGMENTS

We thank all study coordinators and study participants. We are grateful to Kurt Wibmer for providing the cleavage-site and interface mutants and Rui Kong, Nicole Doria-Rose, and John Mascola for providing the fusion peptide, FP9, the FP mutant strain, BG505 Thr514b, and the RSC3 and mutant proteins.

This work was funded by the Hillel Friedland Fellowship (University of the Witwatersrand), the Poliomyelitis Research Foundation (PRF), the South African Medical Research Council (MRC) through the SHIP program, and the NIH through a U01 grant (AI116086-01). P.L.M. acknowledges funding from the Department of Science and Technology through the National Research Foundation (NRF) South African Research Chairs Initiative (SARChI).

## REFERENCES

- Goulder PJ, Lewin SR, Leitman EM. 2016. Paediatric HIV infection: the potential for cure. *Nat Rev Immunol* 16:259–271. <https://doi.org/10.1038/nri.2016.19>.
- Judd A, Ferrand RA, Jungmann E, Foster C, Masters J, Rice B, Lyall H, Tookey PA, Prime K. 2009. Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance. *HIV Med* 10:253–256. <https://doi.org/10.1111/j.1468-1293.2008.00676.x>.
- Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. 2004. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. *Lancet* 364:1236–1243. [https://doi.org/10.1016/S0140-6736\(04\)17140-7](https://doi.org/10.1016/S0140-6736(04)17140-7).
- Muenchhoff M, Adland E, Karimanzira O, Crowther C, Pace M, Csala A, Leitman E, Moonsamy A, McGregor C, Hurst J, Groll A, Mori M, Sinmyee S, Thobakgale C, Tudor-Williams G, Prendergast AJ, Klooverpris H, Roeder J, Leslie A, Shingadia D, Brits T, Daniels S, Frater J, Willberg CB, Walker BD, Ndung'u T, Jooste P, Moore PL, Morris L, Goulder P. 2016. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. *Sci Transl Med* 8:358ra125. <https://doi.org/10.1126/scitranslmed.aag1048>.
- Adland E, Paioni P, Thobakgale C, Laker L, Mori L, Muenchhoff M, Csala A, Clapson M, Flynn J, Novelli V, Hurst J, Naidoo V, Shapiro R, Huang KH, Frater J, Prendergast A, Prado JG, Ndung'u T, Walker BD, Carrington M, Jooste P, Goulder PJ. 2015. Discordant impact of HLA on viral replicative capacity and disease progression in pediatric and adult HIV infection. *PLoS Pathog* 11:e1004954. <https://doi.org/10.1371/journal.ppat.1004954>.
- Roeder JM, Muenchhoff M, Goulder PJ. 2016. Immune activation and paediatric HIV-1 disease outcome. *Curr Opin HIV AIDS* 11:146–155. <https://doi.org/10.1097/COH.0000000000000231>.
- Goo L, Chohan V, Nduati R, Overbaugh J. 2014. Early development of broadly neutralizing antibodies in HIV-1-infected infants. *Nat Med* 20:655–658. <https://doi.org/10.1038/nm.3565>.
- Stephenson KE, Barouch DH. 2016. Broadly neutralizing antibodies for HIV eradication. *Curr HIV/AIDS Rep* 13:31–37. <https://doi.org/10.1007/s11904-016-0299-7>.

9. Kwong PD, Mascola JR. 2018. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. *Immunity* 48:855–871. <https://doi.org/10.1016/j.immuni.2018.04.029>.
10. Landais E, Huang X, Havanar-Daughton C, Murrell B, Price MA, Wickramasinghe L, Ramos A, Bian CB, Simek M, Allen S, Karita E, Kilembe W, Lakhi S, Inambao M, Kamali A, Sanders EJ, Anzala O, Edward V, Bekker LG, Tang J, Gilmour J, Kosakovsky-Pond SL, Phung P, Wrin T, Crotty S, Godzik A, Poignard P. 2016. Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. *PLoS Pathog* 12:e1005369. <https://doi.org/10.1371/journal.ppat.1005369>.
11. Moore PL, Williamson C, Morris L. 2015. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. *Trends Microbiol* 23:204–211. <https://doi.org/10.1016/j.tim.2014.12.007>.
12. Piantadosi A, Chohan B, Panteleeff D, Baeten JM, Mandaliya K, Ndinya-Achola JO, Overbaugh J. 2009. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. *AIDS* 23:579–587. <https://doi.org/10.1097/QAD.0b013e328328f76e>.
13. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? *Nat Med* 15:866–870. <https://doi.org/10.1038/nm.1949>.
14. Wibmer CK, Moore PL, Morris L. 2015. HIV broadly neutralizing antibody targets. *Curr Opin HIV AIDS* 10:135–143. <https://doi.org/10.1097/COH.0000000000000153>.
15. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK, Overbaugh J. 2016. HIV-1 neutralizing antibodies with limited hypermutation from an infant. *Cell* 166:77–87. <https://doi.org/10.1016/j.cell.2016.05.055>.
16. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S, Pegu A, Schmidt SD, Staube RP, Sutton MS, Wang K, Wibmer CK, Haynes BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR. 2016. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. *J Virol* 90:76–91. <https://doi.org/10.1128/JVI.01791-15>.
17. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staube RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. *Nature* 509:55–62. <https://doi.org/10.1038/nature13036>.
18. Moore PL, Gray ES, Sheward D, Madiga M, Ranchoe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L. 2011. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. *J Virol* 85:3128–3141. <https://doi.org/10.1128/JVI.02658-10>.
19. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. *PLoS Pathog* 6:e1001028. <https://doi.org/10.1371/journal.ppat.1001028>.
20. Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O'Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, Zheng A, Joyce MG, Asokan M, Ransier A, Darko S, Migueles SA, Bailer RT, Louder MK, Alam SM, Parks R, Kelsoe G, Von Holle T, Haynes BF, Douek DC, Hirsch V, Seaman MS, Shapiro L, Mascola JR, Kwong PD, Connors M. 2016. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. *Immunity* 45:1108–1121. <https://doi.org/10.1016/j.immuni.2016.10.027>.
21. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. *J Virol* 81:6187–6196. <https://doi.org/10.1128/JVI.00239-07>.
22. Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, Ozorowski G, Soto C, Taft JD, Bailer RT, Cale EM, Chen L, Choi CW, Chuang GY, Doria-Rose NA, Druz A, Georgiev IS, Gorman J, Huang J, Joyce MG, Louder MK, Ma X, McKee K, O'Dell S, Pancera M, Yang Y, Blanchard SC, Mothes W, Burton DR, Koff WC, Connors M, Ward AB, Kwong PD, Mascola JR. 2016. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. *Science* 352:828–833. <https://doi.org/10.1126/science.aae0474>.
23. Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndamambi N, Druz A, Asokan M, Burton DR, Connors M, Karim SS, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL. 2017. Structure and recognition of a novel HIV-1 gp120-gp41 Interface antibody that caused MPER exposure through viral escape. *PLoS Pathog* 13:e1006074. <https://doi.org/10.1371/journal.ppat.1006074>.
24. Derdeyn CA, Moore PL, Morris L. 2014. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. *Curr Opin HIV AIDS* 9:210–216. <https://doi.org/10.1097/COH.0000000000000057>.
25. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. *J Virol* 85:4828–4840. <https://doi.org/10.1128/JVI.00198-11>.
26. Moore PL, Gray ES, Choge IA, Ranchoe N, Mlisana K, Abdool Karim SS, Williamson C, Morris L. 2008. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. *J Virol* 82:1860–1869. <https://doi.org/10.1128/JVI.02187-07>.
27. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Malveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. *Science* 334:1097–1103. <https://doi.org/10.1126/science.1213256>.
28. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* 326:285–289. <https://doi.org/10.1126/science.1178746>.
29. Rusert P, Kouyos RD, Kadelka C, Ebner H, Schanz M, Huber M, Braun DL, Hoze N, Scherrer A, Magnus C, Weber J, Uhr T, Cippa V, Thorball CW, Kuster H, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Boni J, Fellay J, Regoes RR, Gunthard HF, Trkola A, Swiss HIV Cohort Study. 2016. Determinants of HIV-1 broadly neutralizing antibody induction. *Nat Med* 22:1260–1267. <https://doi.org/10.1038/nm.4187>.
30. Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, Kozink DM, Parks RJ, Tomaras GD, Crump JA, Kapiga SH, Sam NE, Kwong PD, Kepler TB, Liao HX, Mascola JR, Haynes BF. 2012. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. *J Virol* 86:4688–4692. <https://doi.org/10.1128/JVI.07163-11>.
31. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. *J Virol* 83:1045–1059. <https://doi.org/10.1128/JVI.01992-08>.
32. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. *J Virol* 85:11502–11519. <https://doi.org/10.1128/JVI.05363-11>.
33. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL. 2013. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. *PLoS Pathog* 9:e1003738. <https://doi.org/10.1371/journal.ppat.1003738>.
34. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Slipeken K, van Gils MJ, de la Pena AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1

- neutralization by a human antibody that binds the gp41-gp120 interface. *Nature* 515:138–142. <https://doi.org/10.1038/nature13601>.
35. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. *Nature* 491:406–412. <https://doi.org/10.1038/nature11544>.
  36. Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessel AJ, Gray MD, Mikell I, Kalamas SA, Haigwood NL, Stamatatos L. 2014. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. *J Virol* 88:12968–12981. <https://doi.org/10.1128/JVI.01816-14>.
  37. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, Kwon YD, Longo NS, Louder MK, Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek M, Burton DR, Koff WC, Mullikin JC, Connors M, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2013. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. *Immunity* 39:245–258. <https://doi.org/10.1016/j.immuni.2013.04.012>.
  38. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. *J Virol* 82:11651–11668. <https://doi.org/10.1128/JVI.01762-08>.
  39. Sather DN, Armann J, Ching LK, Mavranti A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. *J Virol* 83:757–769. <https://doi.org/10.1128/JVI.02036-08>.
  40. Kelsø G, Haynes BF. 2017. Host controls of HIV broadly neutralizing antibody development. *Immunol Rev* 275:79–88. <https://doi.org/10.1111/immr.12508>.
  41. Haynes BF, Verkoczy L. 2014. AIDS/HIV. Host controls of HIV neutralizing antibodies. *Science* 344:588–589.
  42. Milligan C, Omenda MM, Chohan V, Odem-Davis K, Richardson BA, Nduati R, Overbaugh J. 2016. Maternal neutralization-resistant virus variants do not predict infant HIV infection risk. *mBio* 7:e02221-15. <https://doi.org/10.1128/mBio.02221-15>.
  43. Overbaugh J. 2014. Mother-infant HIV transmission: do maternal HIV-specific antibodies protect the infant? *PLoS Pathog* 10:e1004283. <https://doi.org/10.1371/journal.ppat.1004283>.
  44. Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, Read JS, Hawkins E, Bouquin PL, Estep SG, Tomaras GD, Vincent CA, Rathore M, Melvin AJ, Gurnathan S, Lambert J. 2005. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. *J Infect Dis* 192:2129–2133. <https://doi.org/10.1086/498163>.
  45. McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, McNamara J, Read JS, Douglas SD, Deville J, Gurwith M, Gurnathan S, Lambert JS. 2006. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. *AIDS* 20:1481–1489. <https://doi.org/10.1097/01.aids.0000237363.33994.45>.
  46. Fouda GG, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Pollara J, Song LY, Liebl BE, Whitaker K, Shen X, Vandergrift NA, Overman RG, Yates NL, Moody MA, Fry C, Kim JH, Michael NL, Robb M, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Liao HX, Haynes BF, Montefiori DC, Ferrari G, Tomaras GD, Permar SR. 2015. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. *J Infect Dis* 211:508–517. <https://doi.org/10.1093/infdis/jiu444>.
  47. McGuire EP, Fong Y, Toote C, Cunningham CK, McFarland EJ, Borkowsky W, Barnett S, Itell HL, Kumar A, Gray G, McElrath MJ, Tomaras GD, Permar SR, Fouda GG. 2018. HIV-exposed infants vaccinated with an MF59/recombinant gp120 vaccine have higher-magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine. *J Virol* 92:e01070-17. <https://doi.org/10.1128/JVI.01070-17>.
  48. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, Parks R, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, Abdool Karim SS, Kepler TB, Whitesides J, Montefiori D, Moody MA, Liao HX, Haynes BF. 2011. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. *PLoS One* 6:e23532. <https://doi.org/10.1371/journal.pone.0023532>.
  49. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. *Nat Med* 13:1032–1034. <https://doi.org/10.1038/nm1624>.
  50. Montefiori DC. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. *Curr Protoc Immunol Chapter 12:Unit 12.11*.
  51. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L. 2009. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. *J Virol* 83:11265–11274. <https://doi.org/10.1128/JVI.01359-09>.
  52. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, CHAVI 001 Clinical Team Members, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. 2012. The development of CD4 binding site antibodies during HIV-1 infection. *J Virol* 86:7588–7595. <https://doi.org/10.1128/JVI.00734-12>.
  53. Ananworanich J, Apornpong T, Kosalaraksa P, Jaimulwong T, Hansudewechakul R, Pancharoen C, Bunupuradah T, Chandara M, Puthanakit T, Ngampiyasakul C, Wongsawat J, Kanjanavanit S, Luesomboon W, Klanginsirikul P, Ngo-Giang-Huong N, Kerr SJ, Ubolyam S, Mengthaisong T, Gelman RS, Pattanapanyasat K, Saphonn V, Ruxrungtham K, Shearer WT. 2010. Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age. *J Allergy Clin Immunol* 126:1294–1301. <https://doi.org/10.1016/j.jaci.2010.09.038>.
  54. Ssewanyana I, Elrefaei M, Dorsey G, Ruel T, Jones NG, Gasasira A, Kanya M, Nakiwala J, Achan J, Charlebois E, Havlir D, Cao H. 2007. Profile of T cell immune responses in HIV-infected children from Uganda. *J Infect Dis* 196:1667–1670. <https://doi.org/10.1086/522013>.